Silence Therapeutics (SLN) Other Non Operating Income (2020 - 2026)
Silence Therapeutics recorded quarterly Other Non Operating Income of $571000.0 in Q1 2026, up 3105.26% quarter-over-quarter from -$19000.0 in Q4 2025, and up 115.15% year-over-year from $265396.3 in Q1 2025.
Silence Therapeutics' Other Non Operating Income history runs 7 years deep, the most recent figure standing at $571000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 115.15% year-over-year to $571000.0; the TTM figure through Mar 2026 stood at -$5.3 million (down 14797.22% YoY), while the FY2025 annual figure was -$8.5 million, down 289.33% from the prior year.
- Other Non Operating Income came in at $571000.0 for Q1 2026 at Silence Therapeutics, up from -$19000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $1.4 million in Q3 2024 to a low of -$6.6 million in Q2 2025.
- A 5-year average of -$615488.9 and a median of -$19000.0 in 2025 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income soared 14034.01% in 2024 and tumbled 1173.79% in 2025, its largest moves.
- Silence Therapeutics' Other Non Operating Income stood at -$796418.3 in 2022, then slumped by 221.03% to -$2.6 million in 2023, then surged by 140.75% to $1.0 million in 2024, then plunged by 101.82% to -$19000.0 in 2025, then jumped by 3105.26% to $571000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $571000.0, -$19000.0, and $770000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 571,000.00 |
| Dec 31, 2025 | -19,000.00 |
| Sep 30, 2025 | 770,000.00 |
| Jun 30, 2025 | -6.61 Mn |
| Mar 31, 2025 | -3.77 Mn |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 351,000.00 |
| Dec 31, 2023 | -2.56 Mn |
| Sep 30, 2023 | -10,133.48 |
| Jun 30, 2023 | -1.12 Mn |
| Mar 31, 2023 | -1.05 Mn |
| Dec 31, 2022 | -796,418.33 |
| Sep 30, 2022 | -40,070.64 |
| Jun 30, 2022 | -146,080.45 |
| Mar 31, 2022 | 152,969.27 |
| Dec 31, 2021 | -106,492.84 |
| Sep 30, 2021 | -88,229.33 |
| Jun 30, 2021 | -362,011.62 |
| Mar 31, 2021 | -894,919.58 |
| Dec 31, 2020 | 4.08 Bn |
| Sep 30, 2020 | -3.99 Bn |